FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384696564> ?p ?o ?g. }

• W4384696564 abstract "Abstract Background Reduced protection against COVID-19 due to the waning vaccine-induced immunity over time and emergence of immune-evading SARS-CoV-2 variants of concern (VOCs) indicate the need for vaccine boosters. LYB001 is an innovative recombinant SARS-CoV-2 vaccine which displays a repetitive array of the Spike glycoprotein’s receptor binding domain (RBD) on a virus-like particle (VLP) vector to boost the immune system, produced using a Covalink plug-and-display protein binding technology. Methods The safety and immunogenicity of LYB001 as a heterologous booster at an interval of 6-12 months was assessed in 119 participants receiving a booster with (1) 30μg LYB001 ((I-I-30L) or CoronaVac (I-I-C), (2) escalated dose of 60μg LYB001 (I-I-60L) or CoronaVac in a ratio of 2:1 after two-dose primary series of inactivated COVID-19 vaccine in part 1 of this study, or (3) 30μg LYB001 (I-I-I-30L) after three-dose primary series of inactivated COVID-19 vaccine in part 2 of this study. Results A well-tolerated reactogenicity profile was observed for LYB001 as a heterologous booster, with adverse reactions predominantly being mild in severity and transient. The peak neutralizing antibody response was observed at 28 days after booster, with GMT (95%CI) against prototype SARS-CoV-2 being 1237.8 (747.2, 2050.6), 554.3 (374.6, 820.2), 181.9 (107.6, 307.6) and 1200.2 (831.5, 1732.3) in the I-I-30L, I-I-60L, I-I-C, and I-I-I-30L groups, respectively. LYB001 also elicited a cross-neutralizing antibody response against the BA.4/5 strain, dominant during the study period, with GMT being 201.1 (102.7, 393.7), 63.0 (35.1, 113.1), 29.2 (16.9, 50.3) and 115.3 (63.9, 208.1) at 28 days after booster in the I-I-30L, I-I-60L, I-I-C, and I-I-I-30L groups, respectively. Additionally, RBD-specific IFN-γ, IL-2, IL-4 secreting T cells, as measured by ELISpot assay, dramatically increased (more than 10 times versus baseline) at 14 days after a single LYB001 booster. Conclusions Our data confirm the favorable safety and immunogenicity profile of the LYB001 vaccine when used as a heterologous booster, and support the continued clinical development of this promising candidate that utilize VLP platform to provide protection against COVID-19. Trial registration https://www.clinicaltrials.gov (No. NCT05928455 , https://www.clinicaltrials.gov/study/NCT05928455 )" @default.
• W4384696564 created "2023-07-20" @default.
• W4384696564 creator A5001724194 @default.
• W4384696564 creator A5027835055 @default.
• W4384696564 creator A5040166946 @default.
• W4384696564 creator A5051251103 @default.
• W4384696564 creator A5053559346 @default.
• W4384696564 creator A5063789000 @default.
• W4384696564 creator A5076016269 @default.
• W4384696564 creator A5078221491 @default.
• W4384696564 creator A5082549798 @default.
• W4384696564 creator A5085142676 @default.
• W4384696564 creator A5085688428 @default.
• W4384696564 date "2023-07-18" @default.
• W4384696564 modified "2023-09-23" @default.
• W4384696564 title "Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine" @default.
• W4384696564 cites W1991701295 @default.
• W4384696564 cites W2883762793 @default.
• W4384696564 cites W2884027472 @default.
• W4384696564 cites W3025320502 @default.
• W4384696564 cites W3038964751 @default.
• W4384696564 cites W3042383115 @default.
• W4384696564 cites W3090844627 @default.
• W4384696564 cites W3117730334 @default.
• W4384696564 cites W3161351685 @default.
• W4384696564 cites W3190192691 @default.
• W4384696564 cites W4200252704 @default.
• W4384696564 cites W4205240144 @default.
• W4384696564 cites W4205813835 @default.
• W4384696564 cites W4206109560 @default.
• W4384696564 cites W4206675538 @default.
• W4384696564 cites W4206906464 @default.
• W4384696564 cites W4210278951 @default.
• W4384696564 cites W4210704633 @default.
• W4384696564 cites W4220990517 @default.
• W4384696564 cites W4223454164 @default.
• W4384696564 cites W4225124434 @default.
• W4384696564 cites W4225726091 @default.
• W4384696564 cites W4226229183 @default.
• W4384696564 cites W4226343533 @default.
• W4384696564 cites W4226376477 @default.
• W4384696564 cites W4229335678 @default.
• W4384696564 cites W4285606826 @default.
• W4384696564 cites W4285727132 @default.
• W4384696564 cites W4286470414 @default.
• W4384696564 cites W4292764423 @default.
• W4384696564 cites W4302293777 @default.
• W4384696564 cites W4306879897 @default.
• W4384696564 cites W4315630426 @default.
• W4384696564 cites W4320896760 @default.
• W4384696564 cites W4367369001 @default.
• W4384696564 doi "https://doi.org/10.1101/2023.07.17.23292762" @default.
• W4384696564 hasPublicationYear "2023" @default.
• W4384696564 type Work @default.
• W4384696564 citedByCount "0" @default.
• W4384696564 crossrefType "posted-content" @default.
• W4384696564 hasAuthorship W4384696564A5001724194 @default.
• W4384696564 hasAuthorship W4384696564A5027835055 @default.
• W4384696564 hasAuthorship W4384696564A5040166946 @default.
• W4384696564 hasAuthorship W4384696564A5051251103 @default.
• W4384696564 hasAuthorship W4384696564A5053559346 @default.
• W4384696564 hasAuthorship W4384696564A5063789000 @default.
• W4384696564 hasAuthorship W4384696564A5076016269 @default.
• W4384696564 hasAuthorship W4384696564A5078221491 @default.
• W4384696564 hasAuthorship W4384696564A5082549798 @default.
• W4384696564 hasAuthorship W4384696564A5085142676 @default.
• W4384696564 hasAuthorship W4384696564A5085688428 @default.
• W4384696564 hasBestOaLocation W43846965641 @default.
• W4384696564 hasConcept C104317684 @default.
• W4384696564 hasConcept C121332964 @default.
• W4384696564 hasConcept C12590561 @default.
• W4384696564 hasConcept C1276947 @default.
• W4384696564 hasConcept C159047783 @default.
• W4384696564 hasConcept C185592680 @default.
• W4384696564 hasConcept C203014093 @default.
• W4384696564 hasConcept C203165030 @default.
• W4384696564 hasConcept C2522874641 @default.
• W4384696564 hasConcept C2777704310 @default.
• W4384696564 hasConcept C2780115692 @default.
• W4384696564 hasConcept C2780868878 @default.
• W4384696564 hasConcept C32611913 @default.
• W4384696564 hasConcept C55493867 @default.
• W4384696564 hasConcept C71924100 @default.
• W4384696564 hasConcept C8891405 @default.
• W4384696564 hasConceptScore W4384696564C104317684 @default.
• W4384696564 hasConceptScore W4384696564C121332964 @default.
• W4384696564 hasConceptScore W4384696564C12590561 @default.
• W4384696564 hasConceptScore W4384696564C1276947 @default.
• W4384696564 hasConceptScore W4384696564C159047783 @default.
• W4384696564 hasConceptScore W4384696564C185592680 @default.
• W4384696564 hasConceptScore W4384696564C203014093 @default.
• W4384696564 hasConceptScore W4384696564C203165030 @default.
• W4384696564 hasConceptScore W4384696564C2522874641 @default.
• W4384696564 hasConceptScore W4384696564C2777704310 @default.
• W4384696564 hasConceptScore W4384696564C2780115692 @default.
• W4384696564 hasConceptScore W4384696564C2780868878 @default.
• W4384696564 hasConceptScore W4384696564C32611913 @default.
• W4384696564 hasConceptScore W4384696564C55493867 @default.
• W4384696564 hasConceptScore W4384696564C71924100 @default.
• W4384696564 hasConceptScore W4384696564C8891405 @default.

• next